Telomir Pharmaceuticals, Inc.
TELO
$1.26
-$0.03-2.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.02% | 20.09% | 318.57% | 212.64% | 322.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.33% | 7.96% | 198.14% | 133.92% | 212.08% |
| Operating Income | 14.33% | -7.96% | -198.14% | -133.92% | -212.08% |
| Income Before Tax | 37.24% | 51.13% | 13.89% | 33.57% | -26.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.24% | 51.13% | 13.89% | 33.57% | -26.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.24% | 51.13% | 13.89% | 33.57% | -26.94% |
| EBIT | 14.33% | -7.96% | -198.14% | -133.92% | -212.08% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.19% | 54.45% | 20.45% | 38.81% | -18.96% |
| Normalized Basic EPS | 41.17% | 31.30% | -33.83% | -2.13% | -178.51% |
| EPS Diluted | 41.19% | 54.45% | 20.45% | 38.81% | -18.96% |
| Normalized Diluted EPS | 41.17% | 31.30% | -33.83% | -2.13% | -178.51% |
| Average Basic Shares Outstanding | 7.73% | 6.79% | 6.70% | 8.79% | 7.82% |
| Average Diluted Shares Outstanding | 7.73% | 6.79% | 6.70% | 8.79% | 7.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |